Cambridge, Massachusetts-based biotech firm QurAlis raised $88M in oversubscribed Series B funding led by EQT Life Sciences.

 

Cambridge, Massachusetts-based biotech firm QurAlis raised $88M in oversubscribed Series B funding led by EQT Life Sciences.  The company intends to use the proceeds to advance its mission of developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases by moving its two lead candidates into clinical development.  Participants in the funding round include Sanofi Ventures, LSP Dementia Fund, Droia Ventures, Mission BioCapital, INKEF Capital, Amgen Ventures, and others. The Series B round brings its total funds raised to date to $143.5M.   The biotech firm's previous Series A round closed at $42M in May 2020.  QurAlis is also developing a treatment for a type of dementia.